tickrz reports
Edwards Lifesciences Corp (EW)
Healthcare | Health Services
120.06  -0.63%
EW vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
EWSECTORS&P 500
P/E RATIO35.0732.921.12
EV/EBITDA RATIO25.3118.312.66
P/S RATIO7.883.92.25
P/B RATIO8.265.83.45
QUALITY
RETURN ON EQUITY25.45%14.19%13.64%
RETURN ON CAPITAL38.78%20.57%10.09%
NET MARGIN19.22%8.82%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY34%
INTEREST COVERAGE179.3x
CURRENT RATIO3.49
GROWTH
5 YR EPS GROWTH21.4%
5 YR SPS GROWTH12.04%
5 YR BPS GROWTH16.12%
About tickrz
Key Concepts
Great Investors
Edwards Lifesciences Corp 's strong growth translates to a Growth Rank in the top 25% of all stocks
TICKRZBOT SUMMARY
Edwards Lifesciences Corp receives a C ranking in our multi-factor model that blends valuation, moat, operational performance, and financial strength. View the tickrz MFM Screener here. Here's a summary of Edwards Lifesciences Corp's factor rankings that are combined together to calculate the tickrz MFM ranking:

FACTOR RANKINGSFACTOR SCREENER 
TICKRZ MFM RANK C / 328PURE VALUE RANKD / 450
DIVIDEND RANKD / NO DIVIDENDMOAT RANKA / 62
FINANCIAL STRENGTH RANKA / 6GROWTH RANKA / 30
MOMENTUM RANKB / 213
GURU ANALYSIS
Buffett Rank B / 201Peter Lynch Rank A / 77
Edwards Lifesciences Corp ranks 201 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. The stock's average Buffett rank suggests waiting for improved valuation or quality metrics before taking action. The company's moat is strong so it could be worth investigating in the future should its valuation improve.Our Peter Lynch mutli-factor model ranks stocks on their PEG ratio, Financial Strength, margin profile, and their P/Es relative to their respective industry groups. Edwards Lifesciences Corp ranks 77, a relatively strong ranking.
Alex Roepers Rank B / 226Joel Greenblatt Rank C / 239
Alex Roepers, founder of Atlantic Investment Management, looks for stocks trading at low EV/EBITDA multiples with strong and consistent free cash flow. Edwards Lifesciences Corp ranks 226 out of the S&P 500 constituents on our Roepers-inspired multi-factor model.In his best-selling The Little Book that Beats the Market, Greenblatt introduced the Magic Formula, a straightforward approach that ranks stocks on earnings yield and return on invested capital. Edwards Lifesciences Corp places 239 out the S&P 500 consitituents on this ranking methodology.
FACTOR RANKINGS
Value
Pure Value Ranking D / 450
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Edwards Lifesciences Corp's valuation score is comprised of a P/E ratio of 35.1x, a P/B ratio of 8.3x, a P/S ratio of 7.9x, and an EV/EBITDA ratio of 25.3x. Edwards Lifesciences Corp ranks 450 out of the S&P 500 constituents on valuation--a relatively weak score.

Quality
Moat A / 62Financial Strength A / 6
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Edwards Lifesciences Corp appears to have a durable competitive advantage within the Healthcare sector. Edwards Lifesciences Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 179.3x, a debt/equity ratio of 34% and a Moat Rank of 62 translate to a strong Financial Strength score.


Momentum B / 213
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.42% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 213. Based on its 12 month stock performance, Edwards Lifesciences Corp will not appeal to momentum investors.

Yield D / NO DIVIDEND
Value + Yield
Edwards Lifesciences Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

Growth A / 30
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 21.4% 5 year annualized EPS growth, 12% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.1% speak to its impressive growth ranking.

Edwards Lifesciences Corp (EW)
Healthcare | Health Services
120.06  -0.63%


tickrz rank
C
VALUATION RATIOS
P/E Ratio35.07x
P/B Ratio8.26x
P/S Ratio7.88x
EV/EBITDA Ratio25.31x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY34%
INTEREST COVERAGE179.3x
CURRENT RATIO3.49
MOAT
ROE25.45%
ROIC38.78%
Net Margin19.22%
GROWTH
5 YR EPS GROWTH21.4%
5 YR SPS GROWTH12.04%
5 YR BPS GROWTH16.12%

TICKRZ RANK
Edwards Lifesciences Corp receives a C ranking in our multi-factor model that blends valuation, moat, operational performance, and financial strength. View the tickrz MFM Screener here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Edwards Lifesciences Corp's valuation score is comprised of a P/E ratio of 35.1x, a P/B ratio of 8.3x, a P/S ratio of 7.9x, and an EV/EBITDA ratio of 25.3x. Edwards Lifesciences Corp ranks 450 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Edwards Lifesciences Corp ranks 201 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. The stock's average Buffett rank suggests waiting for improved valuation or quality metrics before taking action. The company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Edwards Lifesciences Corp appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Edwards Lifesciences Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 179.3x, a debt/equity ratio of 34% and a Moat Rank of 62 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.42% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 213. Based on its 12 month stock performance, Edwards Lifesciences Corp will not appeal to momentum investors.

VALUE + YIELD
Edwards Lifesciences Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 21.4% 5 year annualized EPS growth, 12% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.1% speak to its impressive growth ranking.